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 Procyanidins have many health benefits. After intake, procyanidins 
are degraded into small metabolites by gastrointestinal microorganisms. 
According to a previous study, 5-(3',4’-Dihydroxyphenyl)-γ-valerolactone 
is the most abundant among these metabolites. The object of this study is to 
determine the effects of DHPV on muscle and whether DHPV could recover 
aged muscle to normal. TGF-β is connected to muscle aging and attenuates 
the muscle differentiation and inhibits myogenesis.  
 In this study, I measured myoD, myogenin, and the myosin heavy 
chain expression level to determine whether DHPV improved the myogenesis 
of C2C12, which had been inhibited by a TGF-β treatment. The results show 
that the RNA and protein expression level of these 3 biomarkers increases in 
 ii 
the DHPV treated group in comparison to TGF-β only treated. In addition, 
DHPV modulated the TGF-β signaling pathway and C2C12 myogenesis by 
regulating p-smad2/3, p-JNK, p-ERK and p-p38 expression. Taken 
together, it may be suggested that DHPV is an ideal therapeutic candidate for 
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 The aging population is growing rapidly worldwide. According to the 
United Nations, the number of people over 60 will rise to more than 2 billion 
by 2050 [1].  Decline of muscle mass and strength is one of the physical 
changes associated with aging and gradually begins at age 40 [2]. Sarcopenia, 
decrease of muscle mass and loss of function, is an age-related senile disease. 
In 2000, the estimated health care costs of sarcopenia in the U. S. was 18.5 
billion dollars [3]. Since impaired physical function lowers the quality of life, 
the importance of studying sarcopenia is growing [4].   
 Skeletal muscle occupies approximately half of the entire body weight 
[5].  Myogenesis is a process to proliferate and differentiate myogenic cells 
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into skeletal muscle as well as to form myotubes and myofibers. [6, 7]. There 
are several biomarkers verified during myogenesis, including myoD, myogenin 
and myosin heavy chain [8].  
 Meanwhile, according to previous research, TGF-β is markedly 
increased in the old muscle cells compared to young ones [9]. TGF-β is a 
well-known muscle differentiation inhibitor [13-20], that mediates the 
expression of myogenic biomarkers by regulating p-smad2/3 and non 
smad2/3 pathways [10, 11]. During muscle differentiation, TGF-β signaling 
activates smad2/3 by up-regulating p-smad2/3, which acts on muscle 
regulatory factors [13, 14], and regulates non-smad pathways including the 
ERK, JNK and p38 pathways [11].  
5-(3',4’-Dihydroxyphenyl)-γ-valerolactone is a main metabolite 
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of procyanidins, which are plentiful in the husks of Yak-Kong, and cocoa. 
Previous study has shown that DHPV was the highest detected metabolite 
after the uptake of cocoa polyphenol in human plasma [12]. According to the 
kinase array conducted in our lab, DHPV attenuates the activity of TGF-β 
receptor 1 by half. In our lab, we have studied DHPV’s beneficial effects such 
as its anti-obesity effects and anti-oxidant effects in neurons, but there are 
no studies of DHPV’s myogenic role. Based on the result of DHPV’s kinase 
array and several health benefits, this study researches the muscle myogenic 
effects of DHPV and investigates the effects of DHPV to indentify the 
molecular mechanisms underlying the myogenic role of DHPV on C2C12 
murine myoblasts.  
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Ⅱ. Materials and methods 
 
1. Chemical and reagents 
 Dulbecco’s modified eagle medium (DMEM), horse serum and fetal 
bovine serum (FBS) were purchased from Thermo Fisher Scientific (Waltham, 
MA, USA).  5-(3’,4’-Dihydroxyphenyl)-gamma-valerolactone (DHPV) 
was purchased from Chemieliva pharmaceutical company (China). All-trans 
retinoic acid was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
TGF-β was purchased from R&D Systems (Minneapolis, MN, USA). The 
sulforhodamine B assay kit was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). The anti-myosin heavy chain, anti-myogenin, anti-myoD, anti-
b-actin, anti-lamin B, anti-smad2/3 antibodies were obtained from Santa 
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Cruz Biotechnology (Santa Cruz, CA, USA). The anti-p-smad2 antibody was 
purchased from Thermo Fisher Scientific (Waltham, MA, USA). The anti-p-
smad3 antibody was obtained from Ab cam (Bristol, UK). 
 
 2. Cell culture and treatments 
 C2C12 murine myoblasts (ATCC, Manassas, VA, USA) were 
cultured in DMEM containing high glucose with FBS. Three days after being 
seeded, the myoblasts were replenished to low glucose DMEM with horse 
serum and each began differentiation. They were replenished everyday. 5 
ng/ml TGF-β, 1 μM DHPV were used to lead to inhibit myogenesis and 
promote myogenesis respectively. And All-trans retinoic acid was used as a 
DHPV’s positive control to promote myogenesis. 
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3. Sulforhodamine B assay (Cell viability) 
 C2C12 cells were cultured in the 96-well plate at a density of 
2.5×10⁵   cells/ml in the presence of DMEM that contained low glucose 
with horse serum for 24 h. They were then analyzed using a Sulforhodamine 
B assay kit according to manufacturer’s instruction. This was done to measure 
cell viability in the presence of TGF-β, DHPV and retinoic acid.  
  
4. Hematoxylin and Eosin staining (H&Estaining) 
 After four days of differentiation, each sample was carefully washed 
twice using PBS. To visualize myotubes and nuclei, hematoxylin and eosin 
(H&E) were used. The hematoxylin was to stain the cytoplasm, and the eosin 
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was for nucleus staining. These myotubes were examined at 100 times 
magnification. 
 
5. Western blot assay 
 Protein extracts were harvested by using RIPA buffer on ice, then 
centrifuged at 13000 g for 10 min. Protein assay reagent kits (Bio-Rad 
Laboratories, Hercules, CA, USA) were used to measure the protein 
concentration, and then the proteins were electrically divided in SDS-
polyacrylamide gel. A transfer was conducted onto a Nitrocellulose blotting 
membrane (GE Healthcare Life Science, Amersham, UK), which was blocked 
in 5% skimmed milk for 1 h, followed by incubation with the primary 
antibodies in a 4 ℃ refrigerator for 16 h. The antibodies were myoD, 
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myogenin, myosin heavy chain, smad2/3, p-smad2, p-smad3, b-actin and 
lamin B, as indicated. After incubation, the membranes were washed 3 times 
with TBS-T for 10 min, and then incubated with secondary antibodies for 1 
h in the presence of 5% skimmed milk. Following this, the membranes were 
washed five times using TBS-T buffer for 8 min. The protein bands were 
discovered through the use of an ECL detection kit (GE healthcare, St, Giles, 
UK) in Chemidoc. Protein quantitative analysis was conducted by Image J 
software (National Institutes of Health, Bethesda, MD, USA).  
  
6. Real-time quantitative PCR 
The RNA of C2C12 cells were collected and isolated in the presence of RNA 
iso Plus (Takara Bio Inc., Shiga, Japan), and then quantified using NanoDrop 
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ND-2000 spectrophotometer (Thermo Fisher Scientific, MA, USA). In 
addition, cDNA synthesis was conducted using a PrimeScript™ 1ststrand 
cDNA Synthesis Kit (Takara, Kyoto, Japan). A real-time quantitative 
polymerase chain reaction (RT-qPCR) was conducted using a Bio-Rad CFX 
96real-time PCR detection system (Bio-Rad) with their respective primers 
and SYBR Green Master Mix (Bio-Rad). The primers used were as follows: 
mouse myoD forward (FW) 5’-GTG GCA GCG AGC ACT ACA GT-3’ and 
mouse myoD reverse (RV) 5’-CTT GCA AAG GAA CTT GGG CTT-3’; 
mouse myogenin forward (FW) 5’-GCA CTG GAG TTC GGT CCC AA-3’ 
and mouse myogenin reverse (RV) 5’-TAT CCT CCA CCG TGA TGC TG-
3’; mouse myosin heavy chain forward (FW) 5’-AAG CGA AGA GTA AGG 
CTG TC-3’ and mouse myosin heavy chain reverse (RV) 5’-CTT GCA AAG 
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GAA CTT GGG CTT-3’; and mouse GAPDH forward (FW) 5’-CAA GGA 
GTA AGA AAC CCT GGA CC-3’ and mouse GAPDH reverse (RV) 5’-
CGA GTT GGG ATA GGG CCT CT-3’. The GAPDH was used as a 
reference gene. 
  
7. Statistical analysis  
 The data was specified as mean ± standard deviation. One-way 
ANOVA test was used for comparative study between each groups, and 







1. DHPV promotes myotube formation and has no toxic effect on 
C2C12 murine myoblasts. 
 To identify the cytotoxicity of DHPV, TGF-β and Retinoic acid on 
C2C12 murine myoblasts, the cell viability was tested using a Sulforhodamine 
B assay. C2C12 myoblasts were treated with 1μM DHPV, 5 ng/ml TGF-β 
and 1μM Retinoic acid for 24 h in a 96 well plate. The four groups were the 
control, TGF-β only, DHPV with TGF-β and Retinoic acid with TGF-β. 
The results showed that they are not toxic to C2C12 myoblasts at each 
concentration (Fig. 1A). The cell viability was indicated as a relative ratio to 
control. 
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 To visualize C2C12 myotube formation, I conducted hematoxylin 
and eosin staining. TGF-β is a well-known myogenesis inhibitor [13-20], 
that diminishes myotube formation in C2C12. According to this result, TGF-
β treatment inhibited cell differentiation and C2C12 myotube formation (Fig. 
1B). A lower density of myotubes was observed in the TGF-β only group 











Figure 1. The cytotoxicity of DHPV and its effect on C2C12 myotube 
formation. (A) The data used to determine whether 1μM DHPV, Retinoic 
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acid and 5 ng/ml TGF-β have a cytotoxic effect on C2C12 cells (A). The cells 
were incubated after treatment for 24 h. The cell viability of the C2C12 cells 
was measured using a Sulforhodamine B assay, and marked according to the 
relatively fold induction compared to the control. Each group was  
triplicated and expressed as means ± standard deviation. (B) Representative 







2. DHPV improves the myoD expression compared to TGF-β 
treatment.  
 The expression of the muscle differentiation biomarker myoD was 
investigated to explore the role of DHPV on myogenesis to counteract TGF-
β. Since myoD usually manifests in the early stage of muscle differentiation, 
the cells were incubated in a differentiation medium containing each sample 
for 24 h. The results showed that TGF-β significantly decreased the myoD 
protein expression level in comparison to the control (Fig. 2A, B). However, 
DHPV and retinoic acid significantly enhanced myoD expression compared 
to TGF-β (Fig. 2A, B). For further study, the mRNA expression level in each 
group was investigated. 24 h after DM, RT-qPCR was conducted. As a result, 
TGF-β significantly down-regulated myoD expression, but DHPV effectively 
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counteracted myoD expression (Fig. 2C). Retinoic acid made myoD 
expression increase slightly, but not significantly (Fig. 2C). Each group was 













Figure 2. DHPV treatment stimulates myoD expression against TGF-β. (A) 
Western blot analysis of the myoD expression cultured in a differentiation 
medium containing each samples for 24 h. Lamin B was used as the loading 
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control. (B) The quantification of the protein bands from (A) (by Image J) 
expressed relative to the control. (C) The myoD mRNA expression level in 










3. DHPV up-regulates the expression of myogenin in spite of TGF-β 
treatment on C2C12 myoblasts. 
 Myogenin is usually expressed in the middle of muscle differentiation. 
Thus, after each sample treatment was treated for 72 h, the myogenin 
expression level was measured. It was found that TGF-β treatment 
significantly attenuated myogenic protein expression in C2C12 myoblasts and 
DHPV and Retinoic acid enhanced myogenin protein expression (Fig. 3A, B). 
RT-qPCR was also conducted after 72 h of sample treatment, showing that 
TGF-β reduced the myogenin mRNA level, and in contrast, DHPV enhanced 








Figure 3. The inhibition of myogenin expression is counteracted by DHPV 
treatment. (A) Myogenin protein expression in C2C12 myoblasts after 72 h 
of DHPV, retinoic acid and TGF-β treatment (n=3). β-actin was used as a 
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loading control. (B) Quantification of myogenin protein expression by Image 
J. (C) Myogenin expression in C2C12 myoblasts after 72 h of DHPV, Retinoic 










4. DHPV treatment couteracts the inhibition of myosin heavy chain 
expression induced by TGF-β. 
 Myosin heavy chain is a biomarker that appears in the last stage of 
muscle differentiation. To determine the myosin heavy chain expression level, 
western blot analysis and RT-qPCR were conducted for each sample after 96 
h of treatment. As with the previous two biomarkers, myosin heavy chain 
protein expression was dramatically attenuated when treated with TGF-β 
only (Fig. 4.A-C). According to the quantification of protein 
bands, treatment with DHPV and Retinoic acid enhanced the myosin heavy 
chain level to higher levels than in the control or similar, which was significant 
(Fig. 4A, B). Even so, myosin heavy chain expression was slightly different 
from the protein level. TGF-β did not reduce the myosin heavy chain level 
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and showed no significance. However, the DHPV and Retinoic acid treatment 
significantly elevated the myosin heavy chain level compared to the control 












      
 
 
Figure 4. DHPV treatment elevates myosin heavy chain expression even in 
TGF-β treated C2C12 myoblasts. (A) Myosin heavy chain protein expression 
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was differentiated for 96 h in C2C12 myoblasts. (B) Quantification of the 
western blot analysis from (A) (n=3).  (C) Myosin heavy chain expression in 











5. DHPV promotes C2C12 myogenesis by regulating both smad 2/3 
signaling and non-smad signaling pathways. 
 TGF-β induces the TGF-β signaling pathway and plays a key role in 
inhibiting myogenesis in C2C12 myoblasts [13-20]. Therefore, I examined 
the expression of phosphorylated smad2/3 which is a well-known 
downstream protein of the TGF-β signaling pathway. The expression of p-
smad2/3 protein decreased when treated with DHPV in contradiction to 
treatment with TGF-β only (Fig. 5A).  MAPK singling pathway is also 
related with TGF-β, which is consist of ERK, JNK and p38 signaling 
pathways [28]. According to this data, DHPV down-regulated 
phosphorylated-JNK and phosphorylated-p38 protein expression against the 
TGF-β treatment. Phosphorylated-ERK slightly increased when DHPV 
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treated compared to TGF-β treatment (Fig. 5B). From these results, it was 















Figure 5. DHPV mediates both smad2/3 signaling pathway and MAPK 
signaling pathways. (A) DHPV decreased p-smad2/3 protein expression 
which was increased by the TGF-β. β-actin was used as a loading control. 
(B) The protein expression of three kinds of MAPK was examined. DHPV 
mediated C2C12 myogenesis via MAPK signaling pathways. β-actin was used 





Figure 6. The summary of the myogenic role of DHPV on C2C12 myogenesis 






 There are several previous studies regarding the health benefits of 
procyanidins such as their neuroprotective effects and anti-atherosclerotic 
ability [23-26]. Furthermore, procyanidins were previously found to have 
antioxidant effects and anti-obesity effects [21, 22]. At this point, the 
question arises as to what other novel health benefits of DHPV may have and 
what type of progress could be made by deactivating TGF-β receptor 1. As I 
metioned earlier, according to the kinase array results, DHPV lowered the 
TGF-β receptor 1 activity by half. Since TGF-β is deeply relevant to old 
muscle [9], DHPV’s role muscle protection against TGF-β was studied.  
 This study explores the myogenic role of DHPV against TGF-β using 
the muscle differentiation facilitator all-trans retinoic acid as a positive 
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control [27]. There are two types of pathways in TGF-β signaling pathway, 
the smad2/3 pathway and non-smad pathways. The results show that DHPV 
promotes the protein expression of three biomarkers of muscle differentiation 
as well as RNA expression, and is usually more effective than retinoic acid. 
DHPV was also confirmed to promote C2C12 myotubes formation more than 
TGF-β inhibits it, showing a high density of differentiated muscle. In the 
signaling pathway, the results show that DHPV regulates TGF-β signaling by 
down-regulating smad2/3 phosphorylation as well as JNK and p38 
phosphorylation and upregulating ERK phosphorylation. In conclusion, 
DHPV promotes C2C12 myogenesis (Fig. 6). 
This study, which is just the beginning of this researcher’s work 
dealing with DHPV’s myogenic function on muscle cells by inhibiting TGF-
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β because only two pathways were studied. As such, further study on other 
TGF-β signaling pathways should be conducted. Since there are no previous 
studies regarding DHPV or procyanidins and myogenesis promotion, these 
results are novel in their discovery of new features of the metabolites of 
natural substances.  
It was observed that DHPV has myogenic effects on C2C12 murine 
myoblasts, and as such, its precursor procyanidins have the possibility to have 
similar effects as DHPV. Therefore, for further study, it is necessary that the 
research into the effects of procyanidins on C2C12 myoblasts should be 
conducted. Whether DHPV directly binds to TGF-β receptors or not should 
be also determined.  
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Administrating DHPV treatment to C2C12 murine myoblasts 
recovers the muscle differentiation suppressed by TGF-β to normal levels and 
promotes myogenesis. This new approach suggests that DHPV may be used 
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프로시아니딘은 약콩 껍질에 풍부한 폴리페놀류의 물질로, 건강에 유익한  
효능이 많이 밝혀져있다. 섭취 후, 프로시아니딘은 장내 균총에 의해 작은 
대사체들로 분해되는데, 선행 연구에 따르면 5-(3',4’-Dihydroxyphenyl)-
γ-valerolactone 은 프로시아니딘에 의해 생성된 대사체들 중 가장 풍부한 
양을 차지한다. 또한 DHPV 는 노인성 근감소증을 일으키는 주요한 
원인으로 꼽히는 TGF-β 의 리셉터의 활성을 절반가량으로 떨어뜨렸는데, 
이러한 kinase array 결과에 기반하여 이 연구가 시작되었다. 이 연구의 
목적은 DHPV 의 TGF-beta 에 의해 분화 억제된 근육세포에서 분화 
회복여부를 관찰히고, DHPV 가 노인성 근 감소증을 진행시키는 분자적 
매커니즘을 조절하여 노인성 근 감소증을 억제하는 것을 밝혀내는데에 있다. 
 39 
 이 연구는 TGF-β에 의해 분화억제된 C2C12 cell에서 DHPV가 
근육분화의 바이오마커인 myoD, myogenic, myosin heavy chain의 발현을 
정상상태만큼 증가시키는 것을 확인하였다. 더 나아가 TGF-β의 하위 
시그널의 단백질의 발현을 조절하며 억제된 myogenesis를 회복하는 것을 
확인하였다.  
본 연구를 통해, 프로시아니딘 대사체 DHPV 가 노화성 근감소를 
억제하는 약리적인 기능을 할 수 있는 가능성을 확인하였다. 
 
 
 
 
 
